Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations

 Shilpa Medicare Limited is pleased to announce that, on successful confirmation of Prequalification of API, Praziquental by WHO-Geneva. Praziquantel is used to treat schistosoma (infection with a type of worm that lives in the bloodstream) and liver fluke (infection with a type of worm that lives in or near the liver). Praziquantel is in a class of medications called anthelmintics. It works by killing the worms
29-07-2021

Shilpa Medicare share price gains 3% on WHO nod for an API

 The share touched a 52-week high of Rs 692.45 and a 52-week low of Rs 317.05 on August 11, 2020, and March 19, 2021, respectively
28-07-2021
Bigul

Shilpa Medicare Ltd - 530549 - Announcement U/R 30 Of The SEBI(LODR) Regulations- Reg.

 Shilpa Medicare Limited (SHILPAMED) today announces receipt of confirmation of WHO - GENEVA approval for API, Tenofovir Disoproxil Fumarate, a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS, under pre- qualification program.
28-07-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 Pursuant to Regulation 30 of SEBI LODR, please find enclosed a copy of the Postal Ballot Notice together with the Explanatory Statement, seeking approval of the Members as per the resolution set out in the Notice of the Postal Ballot.
19-07-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Shareholding for the Period Ended June 30, 2021

 Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here
17-07-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended June 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- V V KRISHNA CHAITANYADesignation :- Company Secretary and Compliance Officer
13-07-2021
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Meeting Updates

 This is to intimate that the Board of Directors at its meeting held today, approved the transfer of API Business of the Company consisting of Unit-1 and Unit-2 situated at Raichur, Karnataka by way of slump sale to a wholly Owned Subsidiary of the Company (to be incorporated) subject to the approval of Shareholders. The detailed disclosure as required under Regulation 30 of SEBI (LODR) Regulations, 2015 is attached hereto as Annexure
12-07-2021
Bigul

Shilpa Medicare Ltd - 530549 - Closure of Trading Window

 Dear Sir/Ma''am, With reference to the above cited subject, it is hereby informed that the trading window of Shilpa Medicare Limited will remain closed for dealing in securities of the Company for all Designated Employees/Persons and their immediate relatives with effect from 01st July, 2021 till the end of 48 hours from the declaration of the financial results for the First Quarter ended 30th June, 2021. This is for your information and records.
29-06-2021
Bigul

Shilpa Medicare Ltd - 530549 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2020-21 issued by M/s P.S. Rao & Associates, Practicing Company Secretaries
26-06-2021
Bigul

Shilpa Medicare Ltd - 530549 - Shilpa Medicare Limited Receives In-Principle Approval From Defence Research & Development Organisation (DRDO) For Technology Transfer, Manufacture And Supply Of 2-Deoxy-D-Glucose (2DG)

 Shilpa Medicare Limited (Shilpa), a research-led global integrated pharmaceutical company, today hereby announces that it has received an in-principle approval from Defence Research & Development Organisation (DRDO) to manufacture and sale of 2-Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for COVID-19 patients in the country. Shilpa Medicare Limited is only the second company in India to have entered into similar arrangement with DRDO. Shilpa has been continuously striving to contribute towards the fight against COVID-19 and this is yet another step by Shilpa after its recently announced arrangement for manufacture and supply of Sputnik V vaccine. This is for your information and doing the needful.
25-06-2021
Next Page
Close

Let's Open Free Demat Account